Psoriasis Clinical Trial
Official title:
Pilot Study of Chinese Medicine Medicated Bath as Complementary Medicine for Mild to Moderate Plaque -Type Psoriasis Patient.
Psoriasis is a chronic inflammatory skin disease. Plague-type psoriasis is the most common
form of the disease, occurring in more than 80% of the cases. This type of psoriasis is
characterized by sharply dermatcated, erythematous, scaling plagues that typically affect the
elbows, knees, scalp, and trunk. Estimates of the prevalence of psoriasis was vary from 0.5%
to 4.6%, with rate varying between countries and races. The prevalence of psoriasis was about
2% in Taiwan. The etiology of psoriasis remains unknown; however, current research mostly
indicated that psoriasis was caused by multiple factors, and it was highly related to Th-17
immunal pathway.Treatment of psoriasis included topical therapy, phototherapy and systemic
therapy. Although beneficial, those therapies often caused undesirable adverse effects.
Traditional Chinese medicine is one of the most fuguently chosen alternative therapies in
China and Taiwan, and psoriasis has been treated for centuries with topical and oral herbal
prepations. Chinese medicine medicated bath is a characteristic therapy of Traditional
Chinese medicine. It combines both hot bath and herbs to enhance absorption of the effective
ingredients of herb. There were reports about the application of Chinese medicine medicated
bath to treat psoriasis patients in China. We also used Chinese medicine medicated bath
(Jing-Fu-Yau-Yu-Bau) as a complementary therapy of psoriasis patients for a long time in
China Medical University Hospital. The patient felt well after using Jing-Fu-Yau-Yu-Bau. The
component of Jing-Fu-Yau-Yu-Bau is paper mulberry leaf. The botanical origin of paper
mulberry leaf is Broussonetia papyrifera (L.) Vent. It can clear heat, cool blood and relieve
itching. Based on the 83 journal paper we searched on PubMed, there had been extracted a
great deal of phenolics, terpenes and flavonoids from paper mulberry leaf that had
antibacterial, antifungal, antioxidant and antineoplastic effects.
This is a single site, randomized, single-blind, controlled pilot study of Jing-
Fu-Yau-Yu-Bau as a complementary therapy to treat mild to moderate plaque- type psoriasis
during an 8-week period. We estimate to enroll 30 subjects (treatment group(N=15); controlled
group(N=15)). We plan to investigate the efficacy and safety of Jing-Fu-Yau-Yu-Bau in Chinese
subjects with mild to moderate plaque-type psoriasis.
This is a single site, randomized, single-blind, controlled pilot study of Jing- Fu-Yau-Yu-Bau as a complementary therapy to treat mild to moderate plaque- type psoriasis during an 8-week period. We estimate to enroll 30 subjects (treatment group(N=15); controlled group(N=15)). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
| Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
| Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
| Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
| Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
| Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
| Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
| Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
| Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
| Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
| Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
| Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
| Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
| Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
| Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |